According to a recent article byBiopharmaTrend(April 24, 2025), Novotech CRO has released a global market analysis identifying over 800 industry-sponsored Idiopathic Pulmonary Fibrosis (IPF) trials initiated since 2020. The Asia-Pacific region leads with 44% of global IPF trial activity, followed by North America (23%) and Europe (21%). The report outlines trial design trends, biomarker-driven stratification, and emerging therapies such as RNAi treatments, monoclonal antibodies, and AI-designed small molecules. With IPF affecting more than 1 million people globally, the analysis offers key insights for biopharma developers navigating this high-need therapeutic space.
Download the article Novotech Report: Over 800 Global IPF Trials Since 2020, Led by Asia-Pacific
Read the full report https://novotech-cro.com/reports/idiopathic-pulmonary-fibrosis-global-clinical-trial-landscape-2025